PPAR-γ gene expression is elevated in skeletal muscle of obese and II diabetic subjects

Diabetes

Volumn 46, Issue 7, 1997, Pages 1230-1234

  Park, Kyong Soo ^b   Ciaraldi, Theodore P ^b   Abrams Carter, Leslie ^b   Mudaliar, Sunder ^b   Nikoulina, Svetlana E ^b   Henry, Robert R ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CELL NUCLEUS RECEPTOR; INSULIN; MESSENGER RNA; PEROXISOME PROLIFERATOR;

ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GLUCOSE CLAMP TECHNIQUE; HUMAN; HUMAN TISSUE; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MUSCLE BIOPSY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SKELETAL MUSCLE;

EID: 0004473133     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.7.1230     Document Type: Article

References (16)

1. Keller H, Walili W: Peroxisome proliferator-activated receptors: a link between endocrinology and nutrition? Trends Endocrinol Metab 4:291-296, 1993
2. Schoonjans K, Staels B, Auwerx J: Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37:907-925, 1996
3. Schoonjans K, Staels B, Auwerx J: The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302:93-109, 1996
4. Spiegelman BM, Flier JS: Adipogenesis and obesity: rounding out the big picture. Cell 87:377-389, 1996
5. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996
6. DeVos P, Lefebvre A-M, Miller SG, Guerre-Millo M, Wong K, Saladin R, Hamann LG, Staels B, Briggs MR, Auwerx J: Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ. J Clin Invest 98:1004-1009, 1996
7. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J Biol Chem 270:12953-12956, 1995
8. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM: The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidenediones. J Med Chem 39:665-668, 1996
9. Vidal-Puig A, Jimenez-Linan M, Lowell BB, Hamann A, Hu E, Spiegelman B, Flier JS, Moller DE: Regulation of PPAR γ gene expression by nutrition and obesity in rodents. J Clin Invest 97:2553-2561, 1996
10. Henry RR, Abrams L, Nikoulina S, Ciaraldi TP: Insulin action and glucose metabolism in nondiabetic control and NIDDM subjects: comparison using human skeletal muscle cell cultures. Diabetes 44:936-946, 1995
11. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose tolerance. Diabetes 28:1039-1057, 1979
12. Thorburn AW, Gumbiner B, Bulacan F, Brechtel G, Henry RR: Multiple defects of muscle glycogen synthase activity contribute to reduced glycogen synthesis in non-insulin dependent diabetes mellitus. J Clin Invest 87:489-495, 1991
13. Freidenberg GR, Henry RR, Klein HH, Reichart DR, Olefsky JR: Decreased kinase activity of insulin receptors from adipocytes of non-insulin-dependent diabetic subjects. J Clin Invest 79:240-250, 1987
14. Wang AM, Doyle MV, Mark DF: Quantitation of mRNA by the polymerase chain reaction. Proc Soc Natl Acad Sci 86:9717-9721, 1989
15. Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, Hsieh L, Greene G, Nimer SD: Isolation of the human peroxisome proliferator activated receptor gamma cDNA expression in hematopoietic cells and chromosomal mapping. Gene Eur 4:281-299, 1995
16. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991